Oral health condition in cancer patients under bisphosphonate therapy
- PMID: 34145489
- DOI: 10.1007/s00520-021-06362-y
Oral health condition in cancer patients under bisphosphonate therapy
Abstract
Objectives: To investigate the association of oral health condition with the occurrence of medication-related osteonecrosis of the jaw (MRONJ) in a cancer population.
Methods: A multicenter cross-sectional study was conducted with cancer patients exposed to bisphosphonates for at least 7 months. Dental and periodontal conditions were assessed by epidemiological indices.
Results: The sample consisted of 80 patients under bisphosphonate therapy, nine of which were allocated to group 1 (with MRONJ) and 71 to group 2 (without MRONJ). Osteonecrosis cases presented 19 decayed, missing, and filled teeth on average. Moderate gingival inflammation was noted in both groups and together with severe inflammation exceeded 50% of the groups. The presence of dental calculus was detected in about half of the individuals in both groups. Shallow periodontal pockets were detected in about 25% of both groups. Deep periodontal pockets were more prevalent among patients with osteonecrosis. Regular oral hygiene was detected in approximately 25% of individuals in both groups. There was a strong positive correlation between the clinical staging of osteonecrosis and decayed, missing, and filled teeth index (DMFTI).
Conclusions: Patients had a poor oral health condition. All but one osteonecrosis case had no previous history of tooth extraction; oral infections seemed to play a major role in the development of bone necrosis. Advanced osteonecrosis stages were associated with a higher DMFTI.
Keywords: Caries; Epidemiology; Oncology; Oral hygiene; Osteonecrosis; Periodontal disease(s)/periodontitis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Wan JT, Sheeley DM, Somerman MJ, Lee JS (2020) Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone Res 8:1–12. https://doi.org/10.1038/s41413-020-0088-1 - DOI
-
- Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E, Alexiou KE, Tsiklakis K, Ardavanis A, Razis E, Athanasiadis I, Droufakou S, Psyrri A, Karamouzis MV, Linardou H, Daliani D, Tzanninis D, Sachanas S, Laschos K, Kyrtsonis MC, Antoniou F, Laskarakis A, Giassas S, Nikolaidi A, Rigakos G, Ntokou A, Migliorati CA, Ripamonti CI (2020) Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis 26:955–966. https://doi.org/10.1111/odi.13294 - DOI - PubMed
-
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014. J Oral and Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031 - DOI
-
- Soares MQS, Van Dessel J, Jacobs R, da Silva Santos PS, Cestari TM, Garlet GP, Duarte MAH, Imada TSN, Lambrichts I, Rubira-Bullen IRF (2018) Zoledronic acid induces site-specific structural changes and decreases vascular area in the alveolar bone. J Oral and Maxillofac Surg 76:1893–1901. https://doi.org/10.1016/j.joms.2018.03.007 - DOI
-
- Katsarelis H, Shah NP, Dhariwal DK, Pazianas M (2015) Infection and medication-related osteonecrosis of the jaw. J Dental Res 94:534–539. https://doi.org/10.1177/0022034515572021 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical